Literature DB >> 14739577

Relationship of pregnancy-associated plasma protein-a to renal function and dialysis modalities.

L Fialová1, M Kalousová, J Soukupová, S Sulková, M Merta, E Jelínková, M Horejsí, P Srámek, I Malbohan, L Mikulíková, V Tesar, T Zima.   

Abstract

BACKGROUND: The aim of the study was to determine pregnancy-associated plasma protein-A (PAPP-A), which was recently described as a new marker of cardiovascular events, in patients with chronic renal insufficiency/failure and to find out its relationship to renal function and to prominent markers of oxidative stress (advanced oxidation protein products--AOPP) and inflammation (C-reactive protein--CRP).
METHODS: The studied group consisted of 36 chronic hemodialysis patients (HD), 10 patients treated with continuous ambulatory peritoneal dialysis (CAPD) and 38 patients with chronic renal insufficiency (CHRI) not yet dialyzed. PAPP-A was measured by Time Resolved Amplified Cryptate Emission technology. Determination of AOPP is based on a spectrophotometric method.
RESULTS: PAPP-A levels are statistically significantly elevated in the both groups of dialyzed patients in comparison with healthy subjects (27.0 +/- 16.5 mIU/l in HD and 14.07 +/- 6.73 mIU/l in CAPD vs. 8.22 +/- 2.7 mIU/l in the control group, p < 0.0001 and p < 0.001, respectively, p < 0.05 HD vs. CAPD). The mean serum PAPP-A levels in the CHRI patients not yet dialyzed were not significantly higher in comparison with the control group (9.72 +/-4.44 vs. 8.22 +/- 2.7 mIU/l, n.s.). In the CHRI not dialyzed patients, we found a significant positive correlation between serum creatinine and PAPP-A levels (r = 0.68, p < 0.05). In comparison with controls, AOPP and CRP levels were significantly higher in HD patients [AOPP 155.0 +/- 37.9 micromol/l, p < 0.0001 vs. controls, CRP 10.0 (4.6- 26.9) mg/l (median, interquartile range), p < 0.0001 vs. controls], CAPD patients [AOPP 118.5 +/- 25.8 micromol/l, p < 0.0001 vs. controls, CRP 7.7 (2.0-18.8) mg/l, p < 0.01 vs. controls] and AOPP levels in chronic renal failure patients not yet dialyzed (98.5 +/- 43.24 micromol/l, p < 0.01 vs. controls). The correlations between PAPP-A and AOPP (r = 0.49, p < 0.05) and PAPP-A and CRP (r = 0.48, p < 0.05) serum concentration were statistically significant in HD patients. In CAPD patients, neither a correlation between PAPP-A and AOPP nor a correlation between PAPP-A and CRP were found.
CONCLUSION: We can conclude that serum PAPP-A levels sensitively reflect the changes in renal function, depend on dialysis modality, and may represent a novel marker associated with inflammation and oxidative stress in chronic renal failure patients. Copyright 2004 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14739577     DOI: 10.1159/000076390

Source DB:  PubMed          Journal:  Kidney Blood Press Res        ISSN: 1420-4096            Impact factor:   2.687


  12 in total

1.  Association of E-selectin gene polymorphism and serum PAPP-A with carotid atherosclerosis in end-stage renal disease.

Authors:  Marianne Samir M Issac; Alaa Afif; Nadida A Gohar; Nahla A Fawzy Fayek; Bahaa Zayed; Heba Sedrak; Lamiaa Adel Salah El Din
Journal:  Mol Diagn Ther       Date:  2014-04       Impact factor: 4.074

2.  Evaluation of Pregnancy-Associated Plasma Protein-A Levels in Patients with Chronic Obstructive Pulmonary Disease and Associations with Disease Severity.

Authors:  Fahrettin Talay; Mehmet Tosun; Zehra Asuk Yaşar; Özlem Kar Kurt; Aysel Karği; Serkan Öztürk; Mehmet Fatih Özlü; Aytekin Alçelik
Journal:  Inflammation       Date:  2016-06       Impact factor: 4.092

3.  Biochemical oxidative stress-related markers in patients with obstructive sleep apnea.

Authors:  Jana Volná; David Kemlink; Marta Kalousová; Jana Vávrová; Veronika Majerová; Otto Mestek; Jana Svarcová; Karel Sonka; Tomás Zima
Journal:  Med Sci Monit       Date:  2011-09

4.  Diagnostic usefulness of pregnancy-associated plasma protein-A in suspected pulmonary embolism.

Authors:  Serdar Berk; Omer Tamer Dogan; Eylem Itir Aydemir; Asli Bingol; Sefa Levent Ozsahin; Ibrahim Akkurt
Journal:  Multidiscip Respir Med       Date:  2013-07-31

5.  The Relation between Pregnancy-Associated Plasma Protein A and Obstructive Sleep Apnea Syndrome.

Authors:  Ali Cengiz; Suat Konuk; Tuncer Tuğ
Journal:  Can Respir J       Date:  2018-06-03       Impact factor: 2.409

6.  Examination of serum pregnancy-associated plasma protein A clinical value in acute coronary syndrome prediction and monitoring.

Authors:  Rafał Nikodem Wlazeł; Jacek Rysz; Marek Paradowski
Journal:  Arch Med Sci       Date:  2013-02-21       Impact factor: 3.318

7.  Biomarkers in Acute Coronary Syndrome.

Authors:  Valentina Loria; Milena Leo; Gina Biasillo; Ilaria Dato; Luigi M Biasucci
Journal:  Biomark Insights       Date:  2008-11-05

8.  Placental growth factor may predict increased left ventricular mass index in patients with mild to moderate chronic kidney disease--a prospective observational study.

Authors:  Martina Peiskerová; Marta Kalousová; Vilem Danzig; Blanka Míková; Magdalena Hodková; Eduard Němeček; Amjad Bani-Hani; David Ambrož; Hana Benáková; Ales Linhart; Tomas Zima; Vladimir Tesař
Journal:  BMC Nephrol       Date:  2013-07-11       Impact factor: 2.388

9.  Placental growth factor, pregnancy-associated plasma protein-A, soluble receptor for advanced glycation end products, extracellular newly identified receptor for receptor for advanced glycation end products binding protein and high mobility group box 1 levels in patients with acute kidney injury: a cross sectional study.

Authors:  Oskar Zakiyanov; Vitezslav Kriha; Jan Vachek; Tomas Zima; Vladimir Tesar; Marta Kalousova
Journal:  BMC Nephrol       Date:  2013-11-04       Impact factor: 2.388

10.  Pregnancy-Associated Plasma Protein A (PAPP-A) Concentration in Population of Healthy Young People: Interactions with Tobacco Smoke and Anti-oxidative Status.

Authors:  Magdalena Szumska; Aleksandra Damasiewicz-Bodzek; Justyna Czubilińska; Michał Długaszek; Kaja Gawlik; Anna Krywult; Konrad Synowiec; Tomasz Wielkoszyński; Krystyna Tyrpień-Golder
Journal:  Cardiovasc Toxicol       Date:  2019-04       Impact factor: 3.231

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.